Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Analgesic Dose of Intrathecal Hydromorphone for Pediatric Posterior Spine Surgery
NCT05552443Phase 4Terminated
- Sponsor
- Mayo Clinic
- Start
- Mar 2023
- Primary completion
- Oct 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label trial of hydromorphone in postoperative pain (12 arms), sponsored by Mayo Clinic. Primary endpoint: Pain Intensity (Area Under the Curve Pain) at 18 hours. Started Mar 2023; status: terminated.
02
Drugs
hydromorphone
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05552443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05552443.